Literature DB >> 11933373

Understanding Parkinson's disease: detection and early disease management.

L A Mackin1.   

Abstract

Parkinson's disease (PD) is a common, debilitating, neurodegenerative disorder characterized by neuronal loss within the basal ganglia and insufficient levels of the neurotransmitter dopamine. Symptoms include resting tremor, rigidity, bradykinesia (slowness of voluntary movement), and postural disturbances. Exact cause is unknown, but theories surrounding environmental or endogenous toxicities have been suggested. Differential diagnoses include genetic and other neurologic disorders that may share symptoms similar to those seen in PD. Clinical progression has been categorized into three phases of the disease: early, nonfluctuating, and fluctuating. Medications generally offer good symptom relief during the early and nonfluctuating phases of the disease. Classifications of anti-PD medications include anticholinergics, dopamine agonists, amantadine, MAO-B inhibitors, levodopa-carbidopa, and Catechol-o-methyl transferase inhibitors. Surgical intervention may be an option for select patients whose conditions are not well controlled though medical management strategies. Primary care providers often can manage patients in the early stage of PD, but later stages require expert neurologic management. Patient/family education and anticipatory guidance is imperative.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11933373

Source DB:  PubMed          Journal:  Lippincotts Prim Care Pract        ISSN: 1088-5471


  4 in total

1.  Dopaminergic toxicity of the herbicide atrazine in rat striatal slices.

Authors:  Nikolay M Filipov; Molly A Stewart; Russell L Carr; Shannon C Sistrunk
Journal:  Toxicology       Date:  2006-12-15       Impact factor: 4.221

Review 2.  Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.

Authors:  Jack J Chen; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

3.  Ventral midbrain astrocytes display unique physiological features and sensitivity to dopamine D2 receptor signaling.

Authors:  Wendy Xin; Kornel E Schuebel; Kam-Wing Jair; Raffaello Cimbro; Lindsay M De Biase; David Goldman; Antonello Bonci
Journal:  Neuropsychopharmacology       Date:  2018-07-13       Impact factor: 7.853

4.  Metacognitive Performance, the Tip-of-Tongue Experience, Is Not Disrupted in Parkinsonian Patients.

Authors:  Justin D Oh-Lee; Sarah M Szymkowicz; Stefanie L Smith; Hajime Otani
Journal:  Parkinsons Dis       Date:  2012-04-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.